Immunomodulator plasmid projected by systems biology as a candidate for the development of adjunctive therapy for respiratory syncytial virus infection.

[1]  A. M. Collier,et al.  Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. , 1979, The New England journal of medicine.

[2]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.

[3]  F. W. Denny,et al.  Acute respiratory infections are the leading cause of death in children in developing countries. , 1986, The American journal of tropical medicine and hygiene.

[4]  R. Fernandez-Botran,et al.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells , 1988, Nature.

[5]  Li Zhu,et al.  Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells , 1997, Gene Therapy.

[6]  E. Gelfand,et al.  Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. , 1997, The Journal of clinical investigation.

[7]  W. Calhoun,et al.  Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. , 1997, American journal of respiratory and critical care medicine.

[8]  W. Fiers,et al.  Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. , 1998, Journal of immunology.

[9]  D. Collen,et al.  Aerosol Gene Transfer With Inducible Nitric Oxide Synthase Reduces Hypoxic Pulmonary Hypertension and Pulmonary Vascular Remodeling in Rats , 2000, Circulation.

[10]  N. Glaichenhaus,et al.  The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Stéphan Vagner,et al.  Irresistible IRES , 2001, EMBO reports.

[12]  R. Lempicki,et al.  Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Philip Smith,et al.  IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. , 2002, Immunity.

[14]  C. Dye,et al.  Estimates of world-wide distribution of child deaths from acute respiratory infections. , 2002, The Lancet. Infectious diseases.

[15]  B. Graham,et al.  NK T Cells Contribute to Expansion of CD8+ T Cells and Amplification of Antiviral Immune Responses to Respiratory Syncytial Virus , 2002, Journal of Virology.

[16]  J. Bijlsma,et al.  Differentiation of naive CD4+ T cells towards T helper 2 cells is not impaired in rheumatoid arthritis patients , 2003, Arthritis research & therapy.

[17]  M. Małecki,et al.  Construction of a bicistronic proangiogenic expression vector and its application in experimental angiogenesis in vivo. , 2003, Acta biochimica Polonica.

[18]  S. Johnston,et al.  Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. , 2003, American journal of respiratory and critical care medicine.

[19]  Mark E. J. Newman.  A measure of betweenness centrality based on random walks , 2005, Soc. Networks.

[20]  D. Mann,et al.  Peptide-based candidate vaccine against respiratory syncytial virus. , 2005, Vaccine.

[21]  R. Karron,et al.  Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. , 2005, The Journal of infectious diseases.

[22]  M. Bushell,et al.  Internal ribosome entry segment-mediated translation during apoptosis: the role of IRES-trans-acting factors , 2005, Cell Death and Differentiation.

[23]  K. Jooss,et al.  Stable antibody expression at therapeutic levels using the 2A peptide , 2005, Nature Biotechnology.

[24]  M. Kolb,et al.  Gene therapy for pulmonary diseases. , 2006, Chest.

[25]  S. L. Hyatt,et al.  Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles , 2006, Gene Therapy.

[26]  Y. Becker.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy—a review , 2006, Virus Genes.

[27]  B. Graham,et al.  Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis , 2007, Journal of Virology.

[28]  C. Cho,et al.  Aerosol delivery of Akt controls protein translation in the lungs of dual luciferase reporter mice , 2007, Gene Therapy.

[29]  Stephen B. Johnson,et al.  Research Paper: Topological Analysis of Large-scale Biomedical Terminology Structures , 2007, J. Am. Medical Informatics Assoc..

[30]  E. Walsh,et al.  Human infant respiratory syncytial virus (RSV)-specific type 1 and 2 cytokine responses ex vivo during primary RSV infection. , 2007, The Journal of infectious diseases.

[31]  E. Piippo-Savolainen,et al.  Wheezy babies—wheezy adults? Review on long‐term outcome until adulthood after early childhood wheezing , 2007, Acta paediatrica.

[32]  Minlie Huang,et al.  Mining physical protein-protein interactions from the literature , 2008, Genome Biology.

[33]  Quan Pan,et al.  PPLook: an automated data mining tool for protein-protein interaction , 2010, BMC Bioinformatics.

[34]  K. Poehling,et al.  The burden of respiratory syncytial virus infection in young children. , 2009, The New England journal of medicine.

[35]  G. Bormans,et al.  Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. , 2009, Human gene therapy.

[36]  F. Schellevis,et al.  Progress in the surveillance of respiratory syncytial virus (RSV) in Europe: 2001-2008. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[37]  R. Flavell,et al.  How are T(H)1 and T(H)2 effector cells made? , 2009, Current opinion in immunology.

[38]  M. He,et al.  PPI Finder: A Mining Tool for Human Protein-Protein Interactions , 2009, PloS one.

[39]  W. Paul,et al.  Differentiation of effector CD4 T cell populations (*). , 2010, Annual review of immunology.

[40]  Gary D. Bader,et al.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..

[41]  Dariusz Plewczynski,et al.  Protein-protein interaction and pathway databases, a graphical review , 2011, Briefings Bioinform..

[42]  G. Laurent,et al.  Nebulisation of Receptor-Targeted Nanocomplexes for Gene Delivery to the Airway Epithelium , 2011, PloS one.

[43]  Miguel A. Andrade-Navarro,et al.  PESCADOR, a web-based tool to assist text-mining of biointeractions extracted from PubMed queries , 2011, BMC Bioinformatics.

[44]  H. Park,et al.  High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice , 2011, PloS one.

[45]  J. O’Shea,et al.  Helper T cell diversity and plasticity. , 2012, Current opinion in immunology.

[46]  Joshua W. Vincentz,et al.  Twist1 Regulates Ifng Expression in Th1 Cells by Interfering with Runx3 Function , 2012, The Journal of Immunology.

[47]  Andrew J. Oler,et al.  The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. , 2012, Immunity.

[48]  S. van Drunen Littel-van den Hurk,et al.  Pathogenesis of respiratory syncytial virus. , 2012, Current opinion in virology.

[49]  Cathy H. Wu,et al.  The eFIP system for text mining of protein interaction networks of phosphorylated proteins , 2012, Database J. Biol. Databases Curation.

[50]  William A Prescott,et al.  Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis , 2012, PharmacoEconomics.

[51]  E. Walsh,et al.  Subunit and virus-like particle vaccine approaches for respiratory syncytial virus. , 2013, Current topics in microbiology and immunology.

[52]  D. Lewis,et al.  Human Neonatal Naive CD4+ T Cells Have Enhanced Activation-Dependent Signaling Regulated by the MicroRNA miR-181a , 2013, The Journal of Immunology.

[53]  R. Karron,et al.  Live-attenuated respiratory syncytial virus vaccines. , 2013, Current topics in microbiology and immunology.

[54]  T. So,et al.  Homeostatic Proliferation of Naive CD4+ T Cells in Mesenteric Lymph Nodes Generates Gut-Tropic Th17 Cells , 2013, The Journal of Immunology.

[55]  S. Jarriault,et al.  Simultaneous Expression of Multiple Proteins Under a Single Promoter in Caenorhabditis elegans via a Versatile 2A-Based Toolkit , 2013, Genetics.

[56]  K. O'Neil,et al.  Inhalation delivery of protein therapeutics. , 2013, Inflammation & allergy drug targets.

[57]  James J. Yoo,et al.  MYOD mediates skeletal myogenic differentiation of human amniotic fluid stem cells and regeneration of muscle injury , 2013, Stem Cell Research & Therapy.

[58]  D. Hayes,et al.  Respiratory syncytial virus: current and emerging treatment options , 2014, ClinicoEconomics and outcomes research : CEOR.

[59]  H. Koskela,et al.  Adults face increased asthma risk after infant RSV bronchiolitis and reduced respiratory health‐related quality of life after RSV pneumonia , 2014, Acta paediatrica.

[60]  T. Lazzarotto,et al.  Respiratory Syncytial Virus Infections in Infants Affected by Primary Immunodeficiency , 2014, Journal of immunology research.

[61]  K. Sala,et al.  Factors associated with disease severity in children with bronchiolitis , 2015, The Journal of asthma : official journal of the Association for the Care of Asthma.